ClinicalTrials.gg
RecruitingNCT07478146CardioParkinsoUpdated Apr 13, 2026

Brief Title: Aerobic Training on Cerebrovascular Function, Cognition and Gait in Parkinson's Disease

An interventional study of Aerobic training and Usual Care in PARKINSON DISEASE (Disorder), sponsored by Raphael Mendes Ritti Dias. Recruiting at 1 site in Brazil. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Raphael Mendes Ritti Dias · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Parkinson Disease with a site in Brazil — 19 open to participants now, 22 under way, 1 of them phase 3. Parkinson Disease · Brazil.

Planned enrollment
37th of 95
40 · median 34
Started
2026
with 5 others
No phase
81 of 103
15 open now
Primary completion
2027-06
later than 18 of 21 live
Registered
98th of 103
by date

Among the 103 studies in Parkinson Disease with a site in Brazil, this one is the 37th largest by planned enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2026, is one of 81 with no phase, reaches primary completion later than 18 of the 21 other live ones, and was the 98th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

19 of the 103 studies in Parkinson Disease with a site in Brazil are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Parkinson Disease with a site in Brazil, or all of them as a file.
02

Study summary

This randomized controlled trial will investigate the effects of a 12-week supervised aerobic training program on cerebrovascular function, peripheral vascular health, cardiovascular autonomic modulation, cognition, non-motor symptoms, sleep, mood, gait biomechanics, quality of life, and body composition in patients with Parkinson's disease (Hoehn \& Yahr stages 1-3). Participants will be randomly allocated to aerobic training or usual care.

Read the detailed description

This is a parallel-group randomized controlled trial Participants (n=40) diagnosed with Parkinson's disease, stages 1-3 on Hoehn \& Yahr scale, will be randomly allocated (1:1 block randomization) to:

  • Aerobic Training Group;
  • Control Group (usual care)

The intervention will last 12 weeks, 3 sessions/week Pre and post-intervention assessments will include:

  • Cerebrovascular function: neurovascular coupling, cerebrovascular reactivity (breath-holding index), dynamic cerebral autoregulation (transfer function analysis), and acute cerebral blood flow response to exercise (transcranial Doppler; vertebral artery flow during silent reading).
  • Peripheral vascular and cardiovascular function: brachial artery flow-mediated dilation, carotid intima-media thickness, resting blood pressure, resting heart rate, cardiorespiratory fitness (VO₂peak), heart rate variability (time and frequency domains), and baroreflex sensitivity.
  • Cognitive performance: Montreal Cognitive Assessment (MoCA), Trail Making Test A and B, and Stroop Color-Word Test.
  • Gait biomechanics: spatiotemporal parameters, 3D kinematics (Vicon system), and kinetics (force platform).
  • Clinical and non-motor symptoms: UPDRS, Non-Motor Symptoms Scale (NMSS), sleep quality (PDSS), anxiety (PAS), depressive symptoms (GDS-15), apathy (Apathy Inventory), fatigue (Parkinson Fatigue Scale), pain (Numeric Rating Scale), and quality of life (PDQ-8).
  • Body composition: quadriceps muscle thickness and subcutaneous adipose tissue thickness assessed by ultrasound.

All experimental sessions will be performed in the "on" medication state

03

Conditions studied

  • PARKINSON DISEASE (Disorder)

Keywords

  • aerobic training
  • exercise
  • rehabilitation
  • Cerebral blood flow
  • neurovascular
  • gait
  • cardiovascular function
  • cognition
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Parkinson's disease
  • Hoehn \& Yahr stages 1-3
  • Stable antiparkinsonian medication for at least 4 weeks
  • (MoCA) score ≥ 18
  • Ability to walk independently (with or without assistive device)
  • Medical clearance for participation in moderate-intensity exercise

Exclusion criteria

Exclusion Criteria:

  • Change in medication
  • to exercise
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Aerobic Training

    Participants will perform supervised aerobic training on a cycle ergometer, 3 times per week for 12 weeks, 40 minutes per session, at perceived exertion 12-13 on Borg scale.

    Behavioral: Aerobic training

  • Other
    Usual Care

    Participants will maintain their usual clinical care and daily activities without structured exercise intervention.

    Behavioral: Usual Care

Interventions

  • BehavioralAerobic training

    Aerobic Exercise Training

  • BehavioralUsual Care

    Usual Care

06

What researchers measure

Primary outcomes

  1. Change in Cerebrovascular Reactivity

    Breath-holding index (dimensionless) assessed by transcranial Doppler

    Time frame: Baseline and 12 weeks

  2. Change in Neurovascular Coupling at 12 Weeks.

    Measured by relative (%) changes in middle cerebral artery blood flow velocity during standardized cognitive tasks (Stroop Color-Word Test, Trail Making Test A and B, and silent reading protocol) using transcranial Doppler ultrasound.

    Time frame: Baseline and 12 weeks

  3. Change in Dynamic Cerebral Autoregulation

    Transfer function gain and phase (0.02-0.4 Hz frequency bands).

    Time frame: Baseline and 12 weeks

  4. Change in Acute Cerebral Blood Flow Response to Exercise

    Change in middle cerebral artery velocity during 6-minute aerobic bout.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change in Brachial Artery Endothelial Function

    Flow-mediated dilation (FMD, %) of the brachial artery assessed by high-resolution vascular ultrasound according to current guidelines.

    Time frame: Baseline and 12 weeks

  2. Change in Brachial Artery Baseline Diameter

    Resting brachial artery diameter (mm) measured by vascular ultrasound

    Time frame: Baseline and 12 weeks

  3. Change in Carotid Intima-Media Thickness

    Common carotid artery intima-media thickness (mm) assessed by B-mode ultrasound.

    Time frame: Baseline and 12 weeks

  4. Change in Resting Blood Pressure

    Systolic and diastolic blood pressure (mmHg).

    Time frame: Baseline and 12 weeks

  5. Change in Resting Heart Rate

    Heart rate (beats per minute).

    Time frame: Baseline and 12 weeks

  6. Change in SDNN

    SDNN derived from beat-to-beat recordings at rest.

    Time frame: Baseline and 12 weeks

  7. Change in Low Frequency Power

    Low-frequency power (ms²) derived from spectral analysis.

    Time frame: Baseline and 12 weeks

  8. Change in Cognitive Function

    Assessed with Montreal Cognitive Assessment that provides a score

    Time frame: Baseline and 12 weeks

  9. Change in Executive Function and Attention

    Assessed with Trail Making Test Part A and Part B (time to completion, seconds).

    Time frame: Baseline and 12 weeks

  10. Change in Non-Motor Symptoms

    Assessed with Non-Motor Symptoms Scale that provides a score. Higher scores indicate greater symptom burden.

    Time frame: Baseline and 12 weeks

  11. Change in Parkinson Disease Severity

    Assessed with the Unified Parkinson's Disease Rating Scale (UPDRS total score).

    Time frame: Baseline and 12 weeks

  12. Change in Anxiety Severity

    Assessed with the Parkinson Anxiety Scale total score (0-48). Higher scores indicate greater anxiety severity.

    Time frame: Baseline and 12 weeks

  13. Change in Depressive Symptoms

    Assessed with Geriatric Depression Scale total score (0-15). Higher scores indicate greater depressive symptom severity.

    Time frame: Baseline and 12 weeks

  14. Change in Apathy

    Assessed with Apathy Inventory total score (0-12). Higher scores indicate greater apathy.

    Time frame: Baseline and 12 weeks

  15. Change in Fatigue

    Parkinson Fatigue Scale total score (range: 16-80). Higher scores indicate greater fatigue severity.

    Time frame: Baseline and 12 weeks

  16. Change in Sleep Quality

    Assessed with Parkinson's Disease Sleep Scale total score (0-150). Lower scores indicate worse sleep quality.

    Time frame: Baseline and 12 weeks

  17. Change in Pain

    Assessed using a Numeric Rating Scale (0-10). Higher values indicate higher pain

    Time frame: Baseline and 12 weeks

  18. Change in Quality of Life

    Assessed with Parkinson's Disease Questionnaire-8 (PDQ-8 total score).

    Time frame: Baseline and 12 weeks

  19. Change in Gait Speed

    Gait speed (meters/second) assessed during overground walking using motion capture analysis.

    Time frame: Baseline and 12 weeks

  20. Change in Gait Kinematics

    Joint angles (degrees) of hip, knee, and ankle during walking assessed by 3D motion capture.

    Time frame: Baseline and 12 weeks

  21. Change in Joint Moments During Walking

    Joint moments (Nm/kg) of the hip, knee, and ankle during walking assessed using force platform analysis.

    Time frame: Baseline and 12 weeks

  22. Change in Muscle Thickness

    Quadriceps muscle thickness (mm) assessed by B-mode ultrasound at standardized anatomical landmarks.

    Time frame: Baseline and 12 weeks

  23. Change in Subcutaneous Adipose Tissue Thickness

    Subcutaneous fat thickness (mm) assessed by B-mode ultrasound at standardized anatomical landmarks.

    Time frame: Baseline and 12 weeks

  24. Change in RMMSD

    RMSSD (ms) derived from beat-to-beat recordings at rest.

    Time frame: Baseline and 12 weeks

  25. Change in High Frequency Power

    High-frequency power (ms²)derived from spectral analysis

    Time frame: Baseline and 12 weeks

  26. Change in Low Frequency/High Frequency ratio

    Low-frequency/high-frequency ratio derived from spectral analysis

    Time frame: Baseline and 12 weeks

  27. Change in Cadence

    Cadence (steps/minute) assessed during overground walking using motion capture analysis.

    Time frame: Baseline and 12 weeks

  28. Change in Stride Length

    Stride length (meters) assessed during overground walking using motion capture analysis.

    Time frame: Baseline and 12 weeks

  29. Change in Double Support Time

    Double support time (% of gait cycle) assessed during overground walking using motion capture analysis

    Time frame: Baseline and 12 weeks

  30. Change in Joint Powers During Walking

    Joint powers (W/kg) of the hip, knee, and ankle during walking assessed using force platform analysis.

    Time frame: Baseline and 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Associação Brasil Parkinson
    São Paulo, São Paulo 04142-092, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized datasets will be avaliable after the completion of the study and publication of main results

Time frame: 6 months after the publication

Access criteria: Open acess

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 16 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 17, 2026
StartActual
Feb 28, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07478146
Lead sponsor
Raphael Mendes Ritti Dias
Responsible party
Raphael Mendes Ritti Dias (Professor, University of Nove de Julho) — Sponsor-investigator
First posted
Mar 17, 2026
Start date
Feb 28, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Raphael M Ritti-Dias, PhD
Contact
raphaelritti@gmail.com
+5519999406878
Hélcio Kanegusuku, PhD
Contact
helciokng@gmail.com
+55 11 99539-9557
Raphael M Ritti-Dias, PhD
principal investigator · University of Nove de Julho

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion